Drug Monograph

Drug/Drug Class:	**Irenka™ (duloxetine hydrochloride) delayed-release capsule / SNRI**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Irenka™ is available in a delayed-release capsule containing 40 mg of duloxetine hydrochloride.
Manufacturer:	Lupin Pharma, Baltimore, MD 21202
Indications:	Irenka™ is indicated for the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, and chronic musculoskeletal pain.
Costs:	$7.27 per capsule of Irenka™. Wholesale Acquisition Cost
Summary of Findings:	The Division recommends adding this drug to the current SNRI clinical edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☒ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer, Pharm. D.
Date: August 21, 2015